Skip to main content
Top
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Osteosarcoma | Research

MFNG is an independent prognostic marker for osteosarcoma

Authors: Yi Gao, Lili Luo, Yuxing Qu, Qi Zhou

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Osteosarcoma (OS) has been the most common malignancy of the bone in children and adolescents, and the unsatisfactory prognosis of OS sufferers has long been a hard nut. Here, we delved into the markers with a prognostic value for predicting the prognosis of OS patients.

Methods

The messenger RNA (mRNA) sequencing data and clinical data of OS were retrieved from a Gene Expression Omnibus (GEO) dataset (GSE39058). Next, prognosis-related genes (PRGs) were filtered with the aid of Kaplan–Meier (K-M) curves and Cox regression analysis (CRA). Later, Gene Ontology (GO) biological process analysis was used in verifying the function of different genes. CCK-8 and cell apoptosis assay were performed to evaluate the function of MFNG in U2OS cells.

Results

Among the obtained genes, Manic Fringe (MFNG) had the closest relevance to prognosis and clinical traits, thus becoming the research object herein. In light of the expression level of MFNG, patients fell into high- and low-MFNG groups. Patients with elevated MFNG expression had a worse prognosis, according to the survival analysis. It was unveiled by the univariate and multivariate analyses that MFNG expression was an independent adverse prognostic factor for disease-free survival in OS patients (p = 0.006). Meanwhile, MFNG expression was linked to gender and tumor recurrence, and it was higher in patients with OS recurrence. Moreover, overexpression of MFNG promoted the cell proliferation and inhibited the cell apoptosis of U2OS cells.

Conclusions

The expression level of MFNG negatively correlated with OS progression, and as an independent adverse prognostic factor for disease-free survival in OS patients. Moreover, MFNG regulated the cell proliferation and apoptosis of OS cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vundavilli H, Datta A, Sima C, Hua J, Lopes R, Bittner M, Miller T, Wilson-Robles HM. Anti-tumor effects of cryptotanshinone (C19H20O3) in human osteosarcoma cell lines. Biomed Pharmacother. 2022;150: 112993.PubMedCrossRef Vundavilli H, Datta A, Sima C, Hua J, Lopes R, Bittner M, Miller T, Wilson-Robles HM. Anti-tumor effects of cryptotanshinone (C19H20O3) in human osteosarcoma cell lines. Biomed Pharmacother. 2022;150: 112993.PubMedCrossRef
2.
go back to reference Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: a surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer. 2022;128(11):2107–18.PubMedCrossRef Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: a surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer. 2022;128(11):2107–18.PubMedCrossRef
3.
go back to reference Folkert IW, Devalaraja S, Linette GP, Weber K, Haldar M. Primary bone tumors: challenges and opportunities for CAR-T therapies. J Bone Miner Res. 2019;34(10):1780–8.PubMedCrossRef Folkert IW, Devalaraja S, Linette GP, Weber K, Haldar M. Primary bone tumors: challenges and opportunities for CAR-T therapies. J Bone Miner Res. 2019;34(10):1780–8.PubMedCrossRef
4.
go back to reference Sun M, Wang Z, Sun W, Chen M, Ma X, Shen J, Fu Z, Zuo D, Wang G, Wang H, Wang C, Yin F, Wang Z, et al. Correlation between patient-derived xenograft modeling and prognosis in osteosarcoma. Orthop Surg. 2022;14(6):1161–6.PubMedPubMedCentralCrossRef Sun M, Wang Z, Sun W, Chen M, Ma X, Shen J, Fu Z, Zuo D, Wang G, Wang H, Wang C, Yin F, Wang Z, et al. Correlation between patient-derived xenograft modeling and prognosis in osteosarcoma. Orthop Surg. 2022;14(6):1161–6.PubMedPubMedCentralCrossRef
5.
go back to reference Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50.PubMedPubMedCentralCrossRef Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50.PubMedPubMedCentralCrossRef
6.
go back to reference Koster R, Panagiotou OA, Wheeler WA, Karlins E, Gastier-Foster JM, Caminada de Toledo SR, Petrilli AS, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patino-Garcia A, et al. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer. 2018; 142(8):1594–1601. Koster R, Panagiotou OA, Wheeler WA, Karlins E, Gastier-Foster JM, Caminada de Toledo SR, Petrilli AS, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patino-Garcia A, et al. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer. 2018; 142(8):1594–1601.
7.
go back to reference Wu CC, Livingston JA. Genomics and the immune landscape of osteosarcoma. Adv Exp Med Biol. 2020;1258:21–36.PubMedCrossRef Wu CC, Livingston JA. Genomics and the immune landscape of osteosarcoma. Adv Exp Med Biol. 2020;1258:21–36.PubMedCrossRef
8.
go back to reference Pennarubia F, Nairn AV, Takeuchi M, Moremen KW, Haltiwanger RS. Modulation of the NOTCH1 pathway by LUNATIC FRINGE is dominant over that of MANIC or RADICAL FRINGE. Molecules. 2021;26(19):5942.PubMedPubMedCentralCrossRef Pennarubia F, Nairn AV, Takeuchi M, Moremen KW, Haltiwanger RS. Modulation of the NOTCH1 pathway by LUNATIC FRINGE is dominant over that of MANIC or RADICAL FRINGE. Molecules. 2021;26(19):5942.PubMedPubMedCentralCrossRef
9.
go back to reference Zhang S, Chung WC, Wu G, Egan SE, Miele L, Xu K. Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction. Cancer Res. 2015;75(10):1936–43.PubMedPubMedCentralCrossRef Zhang S, Chung WC, Wu G, Egan SE, Miele L, Xu K. Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction. Cancer Res. 2015;75(10):1936–43.PubMedPubMedCentralCrossRef
10.
go back to reference Cheng WK, Oon CE, Kaur G, Sainson RCA, Li JL. Downregulation of Manic fringe impedes angiogenesis and cell migration of renal carcinoma. Microvasc Res. 2022;142: 104341.PubMedCrossRef Cheng WK, Oon CE, Kaur G, Sainson RCA, Li JL. Downregulation of Manic fringe impedes angiogenesis and cell migration of renal carcinoma. Microvasc Res. 2022;142: 104341.PubMedCrossRef
11.
go back to reference May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet. 1997;17(4):495–7.PubMedCrossRef May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet. 1997;17(4):495–7.PubMedCrossRef
12.
13.
go back to reference Zhang J, Huang J, Liu W, Ding L, Cheng D, Xiao H. Identification of common oncogenic genes and pathways both in osteosarcoma and ewing’s sarcoma using bioinformatics analysis. J Immunol Res. 2022;2022:3655908.PubMedPubMedCentral Zhang J, Huang J, Liu W, Ding L, Cheng D, Xiao H. Identification of common oncogenic genes and pathways both in osteosarcoma and ewing’s sarcoma using bioinformatics analysis. J Immunol Res. 2022;2022:3655908.PubMedPubMedCentral
14.
go back to reference Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36(2):188–93.CrossRef Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36(2):188–93.CrossRef
15.
go back to reference Wang W, Li S, Lin J, Guo X, Xie Y, Li W, Hao Y, Jiang X. The roles and potential mechanisms of HCST in the prognosis and immunity of KIRC via comprehensive analysis. Am J Transl Res. 2022;14(2):752–71.PubMedPubMedCentral Wang W, Li S, Lin J, Guo X, Xie Y, Li W, Hao Y, Jiang X. The roles and potential mechanisms of HCST in the prognosis and immunity of KIRC via comprehensive analysis. Am J Transl Res. 2022;14(2):752–71.PubMedPubMedCentral
16.
go back to reference Liu H, Shu W, Liu T, Li Q, Gong M. Analysis of the function and mechanism of DIRAS1 in osteosarcoma. Tissue Cell. 2022;76: 101794.PubMedCrossRef Liu H, Shu W, Liu T, Li Q, Gong M. Analysis of the function and mechanism of DIRAS1 in osteosarcoma. Tissue Cell. 2022;76: 101794.PubMedCrossRef
17.
go back to reference Zhang G, Zhu Y, Jin C, Shi Q, An X, Song L, Gao F, Li S. CircRNA_0078767 promotes osteosarcoma progression by increasing CDK14 expression through sponging microRNA-330-3p. Chem Biol Interact. 2022;360: 109903.PubMedCrossRef Zhang G, Zhu Y, Jin C, Shi Q, An X, Song L, Gao F, Li S. CircRNA_0078767 promotes osteosarcoma progression by increasing CDK14 expression through sponging microRNA-330-3p. Chem Biol Interact. 2022;360: 109903.PubMedCrossRef
18.
go back to reference Kokkali S, Kotsantis I, Magou E, Sophia T, Kormas T, Diakoumis G, Spathas N, Psyrri A, Ardavanis A. The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis. Invest New Drugs. 2022;40(3):668–75.PubMedCrossRef Kokkali S, Kotsantis I, Magou E, Sophia T, Kormas T, Diakoumis G, Spathas N, Psyrri A, Ardavanis A. The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis. Invest New Drugs. 2022;40(3):668–75.PubMedCrossRef
19.
go back to reference Zhu J, Simayi N, Wan R, Huang W. CAR T targets and microenvironmental barriers of osteosarcoma. Cytotherapy. 2022;24(6):567–76.PubMedCrossRef Zhu J, Simayi N, Wan R, Huang W. CAR T targets and microenvironmental barriers of osteosarcoma. Cytotherapy. 2022;24(6):567–76.PubMedCrossRef
20.
go back to reference Zhou C, Sun Y, Gong Z, Li J, Zhao X, Yang Q, Yu H, Ye J, Liang J, Jiang L, Zhang D, Shen Z, Zheng S. FAT1 and MSH2 are predictive prognostic markers for chinese osteosarcoma patients following chemotherapeutic treatment. J Bone Miner Res. 2022;37(5):885–95.PubMedCrossRef Zhou C, Sun Y, Gong Z, Li J, Zhao X, Yang Q, Yu H, Ye J, Liang J, Jiang L, Zhang D, Shen Z, Zheng S. FAT1 and MSH2 are predictive prognostic markers for chinese osteosarcoma patients following chemotherapeutic treatment. J Bone Miner Res. 2022;37(5):885–95.PubMedCrossRef
23.
go back to reference Gu W, Xu W, Ding T, Guo X. Fringe controls naive CD4(+)T cells differentiation through modulating notch signaling in asthmatic rat models. PLoS ONE. 2012;7(10): e47288.PubMedPubMedCentralCrossRef Gu W, Xu W, Ding T, Guo X. Fringe controls naive CD4(+)T cells differentiation through modulating notch signaling in asthmatic rat models. PLoS ONE. 2012;7(10): e47288.PubMedPubMedCentralCrossRef
24.
go back to reference Song Y, Kumar V, Wei HX, Qiu J, Stanley P. Lunatic, manic, and radical fringe each promote T and B cell development. J Immunol. 2016;196(1):232–43.PubMedCrossRef Song Y, Kumar V, Wei HX, Qiu J, Stanley P. Lunatic, manic, and radical fringe each promote T and B cell development. J Immunol. 2016;196(1):232–43.PubMedCrossRef
25.
26.
go back to reference Guo S, Quan S, Zou S. Roles of the Notch signaling pathway in ovarian functioning. Reprod Sci. 2021;28(10):2770–8.PubMedCrossRef Guo S, Quan S, Zou S. Roles of the Notch signaling pathway in ovarian functioning. Reprod Sci. 2021;28(10):2770–8.PubMedCrossRef
27.
go back to reference Yang L, Wang X, Sun J, Liu C, Li G, Zhu J, Huang J. Neuritin promotes angiogenesis through inhibition of DLL4/Notch signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2021;53(6):663–72.PubMedCrossRef Yang L, Wang X, Sun J, Liu C, Li G, Zhu J, Huang J. Neuritin promotes angiogenesis through inhibition of DLL4/Notch signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2021;53(6):663–72.PubMedCrossRef
28.
go back to reference Gao Y, Bai L, Shang G. Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20. Aging (Albany NY). 2020;13(2):2668–80.PubMedCrossRef Gao Y, Bai L, Shang G. Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20. Aging (Albany NY). 2020;13(2):2668–80.PubMedCrossRef
30.
go back to reference Guo X, Jiang H, Zong X, Du L, Zhao J, Zhang D, Song G, Jin X. The implication of the notch signaling pathway in biphasic calcium phosphate ceramic-induced ectopic bone formation: a preliminary experiment. J Biomed Mater Res A. 2020;108(5):1035–44.PubMedCrossRef Guo X, Jiang H, Zong X, Du L, Zhao J, Zhang D, Song G, Jin X. The implication of the notch signaling pathway in biphasic calcium phosphate ceramic-induced ectopic bone formation: a preliminary experiment. J Biomed Mater Res A. 2020;108(5):1035–44.PubMedCrossRef
31.
go back to reference Zhang X, Bian H, Wei W, Wang Q, Chen J, Hei R, Chen C, Wu X, Yuan H, Gu J, Lu Y, Cai C, Zheng Q. DLX5 promotes osteosarcoma progression via activation of the NOTCH signaling pathway. Am J Cancer Res. 2021;11(6):3354–74.PubMedPubMedCentral Zhang X, Bian H, Wei W, Wang Q, Chen J, Hei R, Chen C, Wu X, Yuan H, Gu J, Lu Y, Cai C, Zheng Q. DLX5 promotes osteosarcoma progression via activation of the NOTCH signaling pathway. Am J Cancer Res. 2021;11(6):3354–74.PubMedPubMedCentral
32.
go back to reference Dai G, Liu G, Zheng D, Song Q. Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma. Eur J Pharmacol. 2021;899: 174058.PubMedCrossRef Dai G, Liu G, Zheng D, Song Q. Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma. Eur J Pharmacol. 2021;899: 174058.PubMedCrossRef
33.
go back to reference Xia P, Gu R, Zhang W, Sun YF. lncRNA CEBPA-AS1 overexpression inhibits proliferation and migration and stimulates apoptosis of OS cells via notch signaling. Mol Ther Nucleic Acids. 2020;19:1470–81.PubMedCrossRef Xia P, Gu R, Zhang W, Sun YF. lncRNA CEBPA-AS1 overexpression inhibits proliferation and migration and stimulates apoptosis of OS cells via notch signaling. Mol Ther Nucleic Acids. 2020;19:1470–81.PubMedCrossRef
34.
go back to reference Chen W, Liu Y, Chen J, Ma Y, Song Y, Cen Y, You M, Yang G. The Notch signaling pathway regulates macrophage polarization in liver diseases. Int Immunopharmacol. 2021;99: 107938.PubMedCrossRef Chen W, Liu Y, Chen J, Ma Y, Song Y, Cen Y, You M, Yang G. The Notch signaling pathway regulates macrophage polarization in liver diseases. Int Immunopharmacol. 2021;99: 107938.PubMedCrossRef
35.
go back to reference Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19.PubMedCrossRef Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19.PubMedCrossRef
37.
go back to reference Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Sparta A, McCubrey JA, Martelli AM. Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opin Ther Targets. 2013;17(8):921–36.PubMedCrossRef Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Sparta A, McCubrey JA, Martelli AM. Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opin Ther Targets. 2013;17(8):921–36.PubMedCrossRef
38.
go back to reference Amirani E, Hallajzadeh J, Asemi Z, Mansournia MA, Yousefi B. Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy. Int J Biol Macromol. 2020;164:456–67.PubMedCrossRef Amirani E, Hallajzadeh J, Asemi Z, Mansournia MA, Yousefi B. Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy. Int J Biol Macromol. 2020;164:456–67.PubMedCrossRef
39.
go back to reference Li D, Wang D, Liu H, Jiang X. LEM domain containing 1 (LEMD1) transcriptionally activated by SRY-related high-mobility-group box 4 (SOX4) accelerates the progression of colon cancer by upregulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway. Bioengineered. 2022;13(4):8087–100.PubMedPubMedCentralCrossRef Li D, Wang D, Liu H, Jiang X. LEM domain containing 1 (LEMD1) transcriptionally activated by SRY-related high-mobility-group box 4 (SOX4) accelerates the progression of colon cancer by upregulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway. Bioengineered. 2022;13(4):8087–100.PubMedPubMedCentralCrossRef
40.
go back to reference Liu G, Yuan D, Sun P, Liu W, Wu PF, Liu H, Yu GY. LINC00968 functions as an oncogene in osteosarcoma by activating the PI3K/AKT/mTOR signaling. J Cell Physiol. 2018;233(11):8639–47.PubMedCrossRef Liu G, Yuan D, Sun P, Liu W, Wu PF, Liu H, Yu GY. LINC00968 functions as an oncogene in osteosarcoma by activating the PI3K/AKT/mTOR signaling. J Cell Physiol. 2018;233(11):8639–47.PubMedCrossRef
41.
go back to reference Chen C, Guo Y, Huang Q, Wang B, Wang W, Niu J, Lou J, Xu J, Ren T, Huang Y, Guo W. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. Cancer Lett. 2022;536: 215660.PubMedCrossRef Chen C, Guo Y, Huang Q, Wang B, Wang W, Niu J, Lou J, Xu J, Ren T, Huang Y, Guo W. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. Cancer Lett. 2022;536: 215660.PubMedCrossRef
43.
go back to reference Zhou Y, Wang X, Zhang W, Liu H, Liu D, Chen P, Xu D, Liu J, Li Y, Zeng G, Li M, Wu Z, Zhang Y, et al. The immune-related gene HCST as a novel biomarker for the diagnosis and prognosis of clear cell renal cell carcinoma. Front Oncol. 2021;11: 630706.PubMedPubMedCentralCrossRef Zhou Y, Wang X, Zhang W, Liu H, Liu D, Chen P, Xu D, Liu J, Li Y, Zeng G, Li M, Wu Z, Zhang Y, et al. The immune-related gene HCST as a novel biomarker for the diagnosis and prognosis of clear cell renal cell carcinoma. Front Oncol. 2021;11: 630706.PubMedPubMedCentralCrossRef
Metadata
Title
MFNG is an independent prognostic marker for osteosarcoma
Authors
Yi Gao
Lili Luo
Yuxing Qu
Qi Zhou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01139-x

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue